Acrobiosystems Co (301080.SZ) Stock Price

Acrobiosystems Co Price

CLOSED
89.90
​
Market closed

Revenue has compounded at 42.6% per year over the past 7 years to 838.12 M CNY. Earnings per share have grown at 46.7% per year over the last 7 years. Acrobiosystems Co's net margin stands at 19.8%, down from 45.3% several years earlier. Acrobiosystems Co currently offers a dividend yield of about 0.56%. The payout ratio is around 51% of earnings. Analysts set a median price target of 76.28 CNY, implying 15.2% below the current price. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus.

Acrobiosystems Co stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acrobiosystems Co business model & stock analysis

Acrobiosystems Co Ltd develops biomedicine and bio-protein technology, focusing on recombinant proteins, detection services, kits, antibodies, fillers, and culture media. The company serves R&D and production sectors for drug discovery, screening, diagnostic reagents, and clinical trials across tumor, autoimmune, cardiovascular, and infectious disease areas. Its products support early drug development stages and process control in pharmaceutical manufacturing. The firm's main customers are pharmaceutical companies and research institutions requiring advanced biotech solutions for disease treatment development. The company generates revenue through the sale of recombinant proteins, detection services, and related products like kits and antibodies. These offerings are tailored for pharmaceutical firms engaged in drug development and diagnostic reagent optimization. Acrobiosystems' product portfolio targets the biopharmaceutical industry, specifically addressing needs in tumor, autoimmune, cardiovascular, and infectious disease research. The firm's services are utilized in preclinical and clinical trial phases to enhance drug development efficiency. Acrobiosystems' main products include recombinant proteins, kits, antibodies, fillers, and culture media, which are sold to pharmaceutical companies and research organizations. These entities use the products for early-stage drug discovery, verification, and optimization processes. The company's detection services support diagnostic reagent development and drug screening, directly contributing to the pharmaceutical R&D pipeline. The firm's focus on CMC (process control) for drug production ensures its offerings align with critical manufacturing stages in biopharmaceutical development.

Frequently asked questions about Acrobiosystems Co

Analysts currently set an average price target of 72.22 CNY for the Acrobiosystems Co stock (median: 76.28 CNY), implying -17.1 % versus the latest price. The consensus is based on 9 analyst ratings.

9 analysts currently rate the Acrobiosystems Co stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Acrobiosystems Co to generate revenue of 1.08 B CNY and earnings per share of 1.35 CNY.

Converted at the current exchange rate, the Acrobiosystems Co share trades at 12.02 EUR (89.90 CNY).

The expected revenue of Acrobiosystems Co is 1.08 B CNY. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Acrobiosystems Co is 227.36 M CNY. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Acrobiosystems Co is currently 66.43. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Acrobiosystems Co stock.

The price-to-sales ratio (P/S) of Acrobiosystems Co is currently 14.05. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Acrobiosystems Co stock.

The Eulerpool Quality Score for Acrobiosystems Co is 5/10.

The ISIN of Acrobiosystems Co is CNE100004S13. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Acrobiosystems Co is 301080.SZ. The ticker symbol is used to trade Acrobiosystems Co shares on the stock exchange.

Fair ValueTerminal
80.01 CNY
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
1.40 M CNY
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Currency
CNY
Initial public offering
Oct 18, 2021
ISIN
CNE100004S13
Market capitalization
15.03 B CNYLarge Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
66.10
P/Ee 2027
45.63
P/Se
14.05
EV/EBIT
71.78
P/B Ratio
5.66
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
6.10 %
Dividend
Dividend yield
0.56 %
Est. Dividend Yield
0.67 %
Payout Ratio
50.74 %
Dividend growth Ø5Y
-3.43 %
Dividend payments per year
2
Dividend paid since
4 years
Dividend not reduced since
0 years
Dividend increased since
0 years
Dividend withholding tax
10.00 %
Last updated Nov 11, 2026, 1:51 PM

Acrobiosystems Co Peer Group

Acrobiosystems Co FIGI

301080:CH · BBG00XTQHZP5301080:CS · BBG00XTQHZR3301080:C2 · BBG017ZPMFG4